80
Participants
Start Date
July 6, 2023
Primary Completion Date
September 30, 2025
Study Completion Date
September 30, 2025
9MW1911
Participants will receive IV 9MW1911 every 4 weeks.
Placebo
Participants will receive IV placebo every 4 weeks.
Baogang Hospital (No 3 Hospital Affiliated to Medical College of Inner Mongolia), Baotou
China-Japan Friendship Hospital, Beijing
Peking University Shougang Hospital, Beijing
The First Hospital of Changsha, Changsha
The second xiangya hospital of central south university, Changsha
Chengdu Fifth People's Hospital, Chengdu
Chongqing Red Cross Hospital (People's Hospital of Jiangbei District), Chongqing
Fu Yang People's Hospital, Fuyang
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou
The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou
The Second Hospital, University of South China, Hengyang
The Third People's Hospital of Huizhou, Huizhou
Jiangmen Central Hospital, Jiangmen
Liaocheng People's Hospital, Liaocheng
The First Affiliated Hospital of Nanchang University, Nanchang
Pingxiang People's Hospital, Pingxiang
The First Affiliated Hospital of Qiqihar Medical University, Qiqihar
Tongji Hospital of Tongji University, Shanghai
Shengjing Hospital of China Medical University, Shenyang
Suzhou Municipal Hospital, Suzhou
The First Hospital of Shanxi Medical University, Taiyuan
Taizhou Hospital of Zhejiang Province, Taizhou
Mabwell (Shanghai) Bioscience Co., Ltd.
INDUSTRY